PPARγ has been heavily studied in part because the availability of its pharmacological agonists (TZDs) ligands, such as rosiglitazone and pioglitazone, both known to improve insulin resistance and exert anti-inflammatory effects in the adipose tissue [21,22,23] and on a systemic level. Here, PPARG is linked to Insulin resistance.